PROCEPT BioRobotics is executing on a robust growth trajectory, with revenue expanding 19.3% year-over-year to $94.5M in 2026Q2, driven by record HYDROS placements and a favorable mix shift toward higher-margin disposables, which lifted gross margin to 66.0%. ...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 4, 2026 | -$0.47-1.8% vs -$0.46 | $94M+1.9% vs $93M |
Q2 2026 Apr 29, 2026 | -$0.56-1.8% vs -$0.55 | $83M+3.2% vs $81M |
Q1 2026 Feb 25, 2026 | -$0.53-65.6% vs -$0.32 | $76M-18.5% vs $94M |
Q4 2025 Nov 4, 2025 | -$0.38+7.3% vs -$0.41 | $83M-11.1% vs $94M |
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Procept (PRCT) To Contact Him Directly To Discuss Their Options
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation (“PROCEPT” or the “Company”) (NASDAQ: PRCT) on behalf of all purchasers of PROCEPT common stock between February 28, 2024 and February 25, 2026 (the “Class Period”).
Kaplan Fox & Kilsheimer LLP Alerts PROCEPT BioRobotics Corporation (NASDAQ: PRCT) Investors to a Securities Class Action Deadline on September 22, 2026
[url="]The DJS Law Group[/url] reminds investors of a class action lawsuit against PROCEPT BioRobotics Corporation (âProceptâ or âthe Companyâ) (NASDAQ:
Benchmark PRCT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for PROCEPT BioRobotics Corporation (PRCT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $18.43 | $1.05B | -10.72 | 37.22% | -31.02% | -24.89% | — | |
| $402.09 | $142.05B | 51.09 | 20.51% | 28.45% | 17.71% | — | |
| $16.67 | $1.93B | -13.66 | 8.28% | -21.25% | -44% | — | |
| $390.90 | $55.98B | -257.17 | 35.9% | -7.11% | -11.73% | — | |
| $17.50 | $1.2B | -5.76 | 7.93% | -6.08% | -45.97% | — | |
| $141.28 | $268.53B | 19.65 | 5.97% | 22.93% | 29.64% | — |
PROCEPT BioRobotics Corporation (PRCT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
PROCEPT BioRobotics Corporation (PRCT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 4, 2026·SEC
Jun 10, 2026·SEC
Apr 29, 2026·SEC
Get notified when PRCT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PROCEPT BioRobotics Corporation (PRCT) stock FAQ — growth, dividends, profitability & financials explained
PROCEPT BioRobotics Corporation (PRCT) reported $337.3M in revenue for fiscal year 2025. This represents a 5368% increase from $6.2M in 2019.
PROCEPT BioRobotics Corporation (PRCT) grew revenue by 37.2% over the past year. This is strong growth.
PROCEPT BioRobotics Corporation (PRCT) reported a net loss of $109.8M for fiscal year 2025.
PROCEPT BioRobotics Corporation (PRCT) has a return on equity (ROE) of -24.9%. Negative ROE indicates the company is unprofitable.
PROCEPT BioRobotics Corporation (PRCT) had negative free cash flow of $126.0M in fiscal year 2025, likely due to heavy capital investments.
